Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started
UiPath shares surge 12% on Q4 beat & better-than-expected guidance
© Reuters. UiPath shares surge 12% on Q4 beat & better than expected guidance
By Davit Kirakosyan and Senad Karaahmetovic
UiPath Inc (NYSE:PATH) shares jumped more than 12% after-hours following the company's reported Q4 results, with EPS of $0.15 coming in better than the consensus estimate of $0.06. Revenue grew 7% year-over-year to $308.5 million, beating the consensus estimate of $278.64M.
“Fourth quarter fiscal 2023 ARR grew 30 percent year-over-year while revenue outperformance and disciplined cost management resulted in a record fourth quarter non-GAAP operating margin and positive non-GAAP adjusted free cash flow,” said Rob Enslin, UiPath Co-CEO.
The company expects Q1/24 revenue in the range of $270-272M, better than the consensus estimate of $269.14 million. ARR is seen at $1.245-$1.25B as of April 30, 2023.
For the full year, the company expects revenue in the range of $1.253-1.258B, better than the consensus estimate of $1.21B. ARR is seen at $1.425-$1.43B as of January 31, 2024.
Mizuho analysts raised the price target by $1 to $16 per share on a strong quarter and better-than-feared results.
"We are encouraged by the results and the continued GTM repositioning to enterprise/ CSuite, which we believe will help the company drive ARR growth in the current environment. While FY24 guidance was better than feared given macro concerns, the shares are trading now at 6x EV/NTM revenue and 71x NTM FCF (vs peers at 8x NTM Sales and 44x NTM FCF)," they said in a note.
TD Cowen analysts said the quarter was clean "with execution evident in its GTM changes & restructuring efforts." They also raised the price target as he went to $20 from the prior $18 per share.
"Off of a solid 4Q (ARR/rev beat by 2%/11%), PATH's FY24 outlook yields good ARR & revenue starting points that are 3%/4% above consensus w/ adj op income 60% ahead. Still, outlook appears appropriately de-risked for macro uncertainty," the analysts wrote.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.